Updated temporary treatment recommendations for Cerezyme
Press release
22/10/2009 - The temporary treatment recommendations on which patients should receive Cerezyme (imiglucerase) as a priority during the shortage are as follows:
Reporting of side effects will continue as normal, with doctors recording the batch numbers of the medicines in each patient's records. These are temporary recommendations and do not change the currently approved product information for this medicine. The shortage is expected to last until end of 2009.